Portfoliotracker

HitGen Inc.

688222.SS · SHANGHAI · Healthcare Biotechnology 68/100 B

34,90 CNY
▲ +0,25 (+0,72 %)
Closed delayed by 15 min
Price as of 17. 11. 08:00, fetched 17. 11. 14:58
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score68 / 100 Market cap14,5 mld. CNY P/E89,5 Forward P/E63,6 P/S20,5 P/B9,1 EV/EBITDA78,2 Dividend yield0,37 % FCF yield0,35 % EPS0,36 CNY Net margin22,1 % Return on equity10,1 % Beta0,65 Debt / equity0,27
52-week range 21,46 to 47,58
3-month average volume23,2 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; virtual screening; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company's product pipeline also includes HG146, which is in phase Ia clinical trial is a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; and HG 381, an immune-oncology agonist for cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation. In addition, it offers target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services. Further, the company focuses on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases. The company was incorporated in 2012 and is based in Chengdu, China.

Website
hitgen.com
Employees
546
Country
China
Data since
16. 4. 2020

Explore further

Similar companies 688266.SS

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account